Association between statins and clinical outcomes among men with prostate cancer: A systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases

Volumn 19, Issue 2, 2016, Pages 151-162

  Raval, A D ^a,b   Thakker, D ^c   Negi, H ^d   Vyas, A ^e   Salkini, M W ^f,g  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b HEALTHCORE INC   (United States)

^c Capita India   (India)

^d POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^e RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TUMOR MARKER;

ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; DRUG EFFICACY; DRUG USE; HUMAN; META ANALYSIS; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; CANCER STAGING; CAUSE OF DEATH; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS;

BIOMARKERS, TUMOR; CAUSE OF DEATH; COMBINED MODALITY THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS;

EID: 84954493331     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.58     Document Type: Article

References (62)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. International Agency for Research on Cancer: Lyon, France, 2013. Available from: http://globocan.iarc.fr (accessed on 13 June 2015
2. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol 2013; 11: 14-23
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004; 172: 910-914
4. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439
5. Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology 2006; 68: 593-598
6. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816
7. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer 2011; 47: 819-830
8. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012; 3: e248
9. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115: 959-968
10. Cho KJ, Hill MM, Chigurupati S, Du G, Parton RG, Hancock JF. Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. Mol Cell Biol 2011; 31: 1110-1120
11. Brown M, Hart C, Tawadros T, Ramani V, Sangar V, Lau M, et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 2012; 106: 1689-1696
12. Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R, et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 2013; 24: 1427-1434
13. Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, et al. Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU Int 2013; 111 (Pt B): E71-E77
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2009 2014/07; 8: 336-341
15. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from (http://www.cochrane-handbook.org
16. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Ottawa Health Research Institute: Ottawa (ON); 1999. Available from (http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp); (accessed on 10 October 2015
17. McPheeters ML, Kripalani S, Peterson NB, Idowu RT, Jerome RN, Potter SA, et al. Quality improvement interventions to address health disparities. closing the quality gap: revisiting the state of the science. Agency for Healthcare Research and Quality: Rockville, MD, USA, 2012. Evidence Report No. 208. (Prepared by the Vanderbilt University Evidence-based Practice Center under Contract No. 290-2007-10065.) AHRQ Publication No. 12-E009-EF (http://www.effectivehealthcare.ahrq.gov/reports/final.cfm
18. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589-624
19. Harbord RM, Higgins JPT. Meta-regression in Stata. Stata J 2008; 8: 493-519
20. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-893
21. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced metaanalysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008; 61: 991-996
22. Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate 2013; 73: 1214-1222
23. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010; 106: 627-632
24. Macleod LC, Chery LJ, Hu EYC, Lin DW, Zeliadt S, Wright JL. Low density lipoprotine (LDL) level but not statin use is associated with recurrence of prostate cancer after primary treatment. J Urol 2013; 189: E141-E142
25. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010; 116: 3389-3398
26. Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010; 183: 118-124
27. Rioja J, Pinochet R, Savage CJ, Guillonneau BD, Scardino PT, Eastham JA, et al. Impact of statin use on pathologic features in men treated with radical prostatectomy. J Urol 2010; 183(4): e51
28. Ritch CR, Hruby G, Badani KK, Benson MC, McKiernan JM. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int 2011; 108: E211-E216
29. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011; 185: 1268-1273
30. Mass AY, Agalliu I, Laze J, Lepor H. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol 2012; 188: 786-791
31. Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams SG. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int 2013; 111: 954-962
32. Chao C, Williams SG, Xu L, Chen J, Wallner LP, Porter KR, et al. Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy. Cancer Lett 2013; 335: 214-218
33. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 2014; 114: 661-666
34. Ishak-Howard MB, Okoth LA, Cooney KA. Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer. Urology 2014; 83: 1356-1361
35. Danzig MR, Kotamarti S, Ghandour RA, Rothberg MB, Dubow BP, Benson MC, et al. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis 2015; 18: 63-68
36. Katz MO, Zelefsky MJ, Marion C, Yamada Y, Kattan MW, Leibel SA. Statin use is associated with improved biochemical outcome after high-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2003; 57: S271
37. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG, et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006; 26: 298-303
38. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005; 66: 1150-1154
39. Sharma NK, Ruth K, Horwitz E, Buyyounouski M, Pollack A. Statin use prior to radiation therapy for prostate cancer does not improve outcome: the Fox Chase experience. Int J Radiat Oncol Biol Phys 2006; 66: S366
40. Soto DE, Daignault S, Sandler HM, Ray ME. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009; 73: 158-162
41. Shippy AM, Katz MS, Yamada Y, Feder DJ, Zelefsky MJ. Statin use and clinical outcomes after high dose radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007; 69: S113
42. Kollmeier MA, Katz MS, Mak K, Yamada Y, Feder DJ, Zhang Z, et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 713-718
43. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28: 2653-2659
44. Cuaron J, Pei X, Cohen GN, Cox BW, Yamada Y, Zelefsky MJ, et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy 2015; 14: 179-184
45. Oh DS, Koontz B, Freedland SJ, Gerber L, Patel P, Lewis S, et al. Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. World J Urol 2015; 33: 93-97
46. Zaorsky NG, Buyyounouski MK, Li T, Horwitz EM. Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys 2012; 84: e13-e17
47. Cattarino S, Seisen T, Drouin SJ, Renard-Penna R, Leon P, Comperat E, et al. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study. Can J Urol 2015; 22: 7703-7708
48. Misrai V, Do C, Lhez JM, Elman B, Latorzeff I, Portalez D, et al. Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?. Prog Urol 2012; 22: 273-278
49. Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 2011; 14: 63-68
50. Song C, Park S, Park J, Shim M, Kim A, Jeong IG, et al. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. Prostate 2015; 75: 211-217
51. Kontraros M, Varkarakis I, Ntoumas K, Deliveliotis C. Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy. Urol Int 2013; 90: 263-269
52. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 2014; 32: 5-11
53. Caon J, Paquette M, Hamm J, Pickles T. Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy?. Prostate Cancer 2014; 2014: 184297
54. Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of betablockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014; 65: 635-641
55. Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, et al. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis 2013; 16: 367-371
56. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med 2013; 5: 173sr2
57. American Cancer Society. Cancer Facts & Figures 2015. American Cancer Society: Atlanta, GA, USA, 2015
58. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012; 104: 1335-1342
59. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD004816. DOI: 10.1002/14651858. CD004816.pub5
60. Stuart BC, Davidoff AJ, Erten MZ. Changes in medication management after a diagnosis of cancer among medicare beneficiaries with diabetes. J Oncol Pract 2015; 11: 429-434
61. Chustecka Z. Comparing costs of new drugs in prostate cancer [Internet]. 2015. Available from: http://www.medscape.com/viewarticle/779717
62. Jacob BJ, Sutradhar R, Moineddin R, Baxter NN, Urbach DR. Methodological approaches to population based research of screening procedures in the presence of selection bias and exposure measurement error: colonoscopy and colorectal cancer outcomes in Ontario. BMC Med Res Methodol 2013; 13: 59,2288-13-59